Clinical Trials on Herpes Simiae (B Virus)

Total 2522 results

The University of Texas Medical Branch, Galveston
Shriners Hospitals for Children

Completed

Review of Human Herpes Viruses in Burns

Burns | Chickenpox | Cytomegalovirus | Herpes Simplex Virus | Varicella-zoster Virus | Human Herpes Virus
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Herpes Zoster | Herpes Zoster Vaccine

Canada, Spain, Korea, Republic of, United Kingdom, France, Czechia
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Estonia, Canada
Ohio State University

Completed

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

Herpes Zoster Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

Herpes Zoster | Herpes Zoster-related Complications
Institut Pasteur

Recruiting

Simian Foamy Virus Transmission to Humans

Simian Foamy Virus Infection (Disorder)

Cameroon
GlaxoSmithKline

Completed

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

Herpes Zoster | Herpes Zoster Vaccine

United States, Canada, Belgium
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
Centrexion Therapeutics

Terminated

Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

Acute-onset Herpes Zoster Pain

Australia
Tanta University

Not yet recruiting

Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain.

Acute Herpes Zoster Pain Managment
The University of Hong Kong

Recruiting

Epidural Platelet Rich Plasma Injection for Herpes Zoster

Acute Herpes Zoster Neuropathy

Hong Kong
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Herpes Zoster
Lee's Pharmaceutical Limited

Not yet recruiting

Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer

Herpes Zoster
Wuhan BravoVax Co., Ltd.
Shanghai BravoBio Co., Ltd.

Not yet recruiting

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

Herpes Zoster
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Herpes Zoster

China
GlaxoSmithKline

Completed

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Sweden, Korea, Republic of, Brazil, Mexico, Canada, Italy, France, Czechia, Estonia, Hong Kong, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Herpes Zoster

United States, Australia, Finland, Germany, Japan, Taiwan, Sweden, Spain, Korea, Republic of, Brazil, Mexico, Italy, Canada, Czechia, Estonia, France, Hong Kong, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Herpes Zoster

Spain, Canada, Belgium, Finland, Korea, Republic of, Panama, Taiwan
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Herpes Zoster
EMS

Completed

Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster

Herpes Zoster

Brazil
University of Sydney

Completed

Herpes Zoster Vaccine for Bone Marrow Transplant Donors (VZV-Zostavax)

Herpes Zoster

Australia
GlaxoSmithKline

Completed

Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects

Herpes Zoster

Germany, Czechia, Sweden, Netherlands
Curevo Inc
Green Cross Corporation; Mogam Biotechnology Research Institute

Active, not recruiting

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Herpes Zoster | Shingles

United States
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles

Herpes Zoster

Spain, Panama, Mexico, Russian Federation, Finland, Estonia, Hong Kong, United Kingdom
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Herpes Zoster

United States, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Herpes Zoster

United States, Germany, Estonia, Canada
Maruho Co., Ltd.

Completed

Phase III Study of ASP2151 in Herpes Zoster Patients

Herpes Zoster

Japan
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years

Herpes Zoster

Japan
GlaxoSmithKline

Completed

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

Herpes Zoster

United States, Estonia
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

Herpes Zoster

Spain, Taiwan, Italy, Canada, Belgium, Finland, Korea, Republic of, Panama, Czechia
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

Herpes Zoster

Australia
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Herpes Zoster

United States, Australia, France, Spain, Finland, Estonia, Russian Federation, Taiwan, Belgium, Korea, Republic of, Czechia, Germany, Hong Kong, Israel, Turkey, United Kingdom, Greece, Romania, Netherlands, Italy, South Africa, Ca... and more
GlaxoSmithKline

Completed

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

Herpes Zoster

United States
Yung Shin Pharm. Ind. Co., Ltd.

Completed

A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster (Vacyless®)

Herpes Zoster

Taiwan
Fundación Nacional para la Enseñanza y la Investigación...

Unknown

Occlusion vs Standard Treatment for the Treatment of Herpes Zoster

Herpes Zoster

Mexico
Roxane Laboratories

Completed

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

Herpes Zoster | Genital Herpes | Shingles

United States
University of Colorado, Denver
GlaxoSmithKline

Completed

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Herpes Zoster | Shingles

United States
Bristol-Myers Squibb

Completed

A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster

Herpes Zoster | Shingles
Northwestern University
Bausch & Lomb Incorporated

Terminated

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

Herpes Zoster Keratitis

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage (CeVOT-Her-Zo)

Herpes Zoster

Italy
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

Herpes Zoster

Germany, Czechia, Sweden
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Herpes Zoster

India
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Herpes Zoster

China
Jiangsu Province Centers for Disease Control and...

Completed

Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age

Herpes Zoster

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Herpes Zoster

United States, Spain, Czechia
Astellas Pharma Inc

Completed

Dose-finding Study of ASP2151 in Subjects With Herpes Zoster

Herpes Zoster

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

Herpes Zoster

Russian Federation, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Herpes Zoster

United States
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

Herpes Zoster

3

Subscribe